21 January 2019
The UK National Health Service (NHS) has announced contingency plans to ensure there is no disruption to medicines supply for patients in the event of a no-deal Brexit.
24 October 2018
The UK pharmaceutical industry bodies have told MPs that patients may need to stockpile their own drugs in case of a no-deal Brexit, which could result in ‘catastrophic consequences’ for...
28 March 2018
A new survey conducted by TraceLink, a track and trace network, has revealed inconsistency in the life science industry’s readiness to comply with serialisation deadlines in the US and EU.
20 March 2018
Tilray has signed a binding letter of intent (LoI) with Sandoz Canada to advance the development and commercialisation of medical cannabis products in the country.
27 February 2018
Manufacturing solutions provider ACG group has signed a memorandum of understanding (MoU) with secure molecular technologies firm Applied DNA Sciences for the development of molecularly tagged empty hard-shell capsules.
17 January 2018
Sun Pharmaceutical Industries’ wholly owned subsidiaries have reached an agreement with Ironwood Pharmaceuticals and Allergan to resolve the patent litigation associated with the submission of an abbreviated new drug application...
3 January 2018
US-based ANI Pharmaceuticals has purchased the rights from AstraZeneca to market Atacand, Atacand HCT, Arimidex and Casodex tablets in the country.
6 June 2017
Canadian research-based pharmaceutical firm Purdue Pharma has entered a distribution and licence agreement to distribute, promote, market and sell Swiss pharmaceutical group Helsinn’s Aloxi (palonosetron hydrochloride) in the country.
5 June 2017
Danish-based Veloxis Pharmaceuticals’ US subsidiary has signed two different exclusive licence, supply and distribution agreements to register, commercialise and distribute Envarsus XR in China, Taiwan and Canada.
23 May 2017
Sanofi and Regeneron Pharmaceuticals’ drug Kevzara (sarilumab) has received the US Food and Drug Administration (FDA) approval to treat adult patients affected with moderately to severely active rheumatoid arthritis (RA).